Literature DB >> 25035282

Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.

Guru Sonpavde1, Joaquim Bellmunt2, Jonathon E Rosenberg3, Ashley M Regazzi3, Dean F Bajorin3, Toni K Choueiri4, Angela Q Qu4, Guenter Niegisch5, Peter Albers5, Andrea Necchi6, Giuseppe Di Lorenzo7, Ronan Fougeray8, Yu-Ning Wong9, Srikala S Sridhar10, Yoo-Joung Ko11, Matthew I Milowsky12, Matthew D Galsky13, Gregory R Pond14.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25035282     DOI： 10.1016/j.clgc.2014.03.016

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  6 in total

1.  Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change?

Authors:  Guru Sonpavde; Joaquim Bellmunt
Journal:  Oncologist       Date:  2015-04-06

2.  Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma.

Authors:  Guru Sonpavde; Gregory R Pond; Jonathan E Rosenberg; Dean F Bajorin; Toni K Choueiri; Andrea Necchi; Giuseppe Di Lorenzo; Joaquim Bellmunt
Journal:  J Urol       Date:  2015-08-17       Impact factor: 7.450

3.  Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy.

Authors:  Andrea Necchi; Gregory R Pond; Patrizia Giannatempo; Giuseppe Di Lorenzo; Bernhard J Eigl; Jenn Locke; Sumanta K Pal; Neeraj Agarwal; Austin Poole; Ulka N Vaishampayan; Guenter Niegisch; Syed A Hussain; Parminder Singh; Joaquim Bellmunt; Guru Sonpavde
Journal:  Clin Genitourin Cancer       Date:  2014-09-23       Impact factor: 2.872

4.  Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.

Authors:  Matthew D Galsky; Sumanta Kumar Pal; Shih-Wen Lin; Sarika Ogale; Marko Zivkovic; Joseph Simpson; Christina Derleth; Christina Schiff; Guru Sonpavde
Journal:  Bladder Cancer       Date:  2018-04-26

5.  Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).

Authors:  M De Santis; P J Wiechno; J Bellmunt; C Lucas; W-C Su; L Albiges; C-C Lin; E Senkus-Konefka; A Flechon; L Mourey; A Necchi; W C Loidl; M M Retz; N Vaissière; S Culine
Journal:  Ann Oncol       Date:  2015-12-16       Impact factor: 32.976

6.  Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study.

Authors:  Giuseppe Di Lorenzo; Carlo Buonerba; Teresa Bellelli; Concetta Romano; Vittorino Montanaro; Matteo Ferro; Alfonso Benincasa; Dario Ribera; Giuseppe Lucarelli; Ottavio De Cobelli; Guru Sonpavde; Sabino De Placido
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.